EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions

Lisa E Manhart iD, Gina Leipertz, Olusegun O Soge, Stephen J Jordan, Candice McNeil, Preeti Pathela, Hilary Reno, Karen Wendel, Anika Parker, William M Geisler, Damon Getman, Matthew R Golden und 1 weitere

Clinical Infectious Diseases · 17.11.2023 · 77 (10) · 1449-1459

DOI: 10.1093/cid/ciad405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.07.2023. Verfasst von Lisa E Manhart und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Center for AIDS and STD, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Urethritis, Mycoplasma genitalium, Uterine Cervicitis, Sexual Health. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hologic, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats, yet there is no systematic surveillance to monitor change.

Methods

We initiated surveillance in sexual health clinics in 6 cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide-resistance mutations (MRMs) by nucleic acid amplification testing. We used Poisson regression to estimate adjusted prevalence ratios (aPRs) and 95% CIs, adjusting for sampling criteria (site, birth sex, symptom status).

Results

From October–December 2020 we tested 1743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black persons, and 43.8% from symptomatic patients. MG prevalence was 16.6% (95% CI: 14.9–18.5%; site-specific range: 9.9–23.5%) and higher in St Louis (aPR: 1.9; 1.27–2.85), Greensboro (aPR: 1.8; 1.18–2.79), and Denver (aPR: 1.7; 1.12–2.44) than Seattle. Prevalence was highest in persons <18 years (30.4%) and declined 3% per each additional year of age (aPR: .97; .955–.982). MG was detected in 26.8%, 21.1%, 11.8%, and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR: 1.7; 1.22–2.50) and chlamydia (aPR: 1.7; 1.13–2.53). MRM prevalence was 59.1% (95% CI: 53.1–64.8%; site-specific range: 51.3–70.6%). MRMs were associated with vaginitis (aPR: 1.8; 1.14–2.85), cervicitis (aPR: 3.5; 1.69–7.30), and PID cervicitis (aPR: 1.8; 1.09–3.08).

Conclusions

MG infection is common in persons at high risk of sexually transmitted infections; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UrethritisMycoplasma genitaliumUterine CervicitisSexual HealthPelvic Inflammatory DiseaseVaginitisMycoplasma InfectionsFemaleHumansMaleAnti-Bacterial AgentsMacrolidesDrug Resistance, BacterialPrevalence

Stichwörter der Autor:innen

Mycoplasma genitaliumantimicrobial resistanceepidemiologysurveillance

Substanzen

Anti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • Department of Epidemiology and Center for AIDS and STD, University of Washington, Seattle, Washington, USA.
  • Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA.
  • Department of Global Health, and Division of Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Division of Infectious Diseases, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Department of Medicine, Section on Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID-Profile: Lisa E Manhart

Förderung

  • Hologic, Inc

Zitieren

APA

Manhart, L. E., Leipertz, G., Soge, O. O., Jordan, S. J., McNeil, C., Pathela, P., Reno, H., Wendel, K., Parker, A., Geisler, W. M., Getman, D., Golden, M. R., & MyGeniUS Study Team (2023). Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions. Clinical Infectious Diseases, 77(10), 1449-1459. https://doi.org/10.1093/cid/ciad405

Vancouver

Manhart LE, Leipertz G, Soge OO, Jordan SJ, McNeil C, Pathela P, et al. Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions. Clinical Infectious Diseases. 2023;77(10):1449-1459. doi:10.1093/cid/ciad405

BibTeX
@article{Manhart2023,
  author = {Manhart, Lisa E and Leipertz, Gina and Soge, Olusegun O and Jordan, Stephen J and McNeil, Candice and Pathela, Preeti and Reno, Hilary and Wendel, Karen and Parker, Anika and Geisler, William M and Getman, Damon and Golden, Matthew R and MyGeniUS Study Team, MyGeniUS Study Team},
  title = {Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {10},
  pages = {1449--1459},
  doi = {10.1093/cid/ciad405}
}
Kostenlos starten →